{'fraction_non_alphanumeric': 0.024271844660194174, 'fraction_numerical': 0.019417475728155338, 'mean_word_length': 5.991525423728813, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cost‐Effectiveness Analysis of HLA–B5801 Genotyping in the Treatment of Gout Patients With Chronic Renal Insufficiency in Korea

Allopurinol‐induced severe cutaneous adverse reactions (SCARs) are relatively rare but cause high rates of morbidity and mortality. Studies have shown that the HLA–B5801 allele and renal impairment are strongly associated with SCARs. Recent American College of Rheumatology guidelines recommend that, prior to treatment with allopurinol, the HLA–B5801 genotype of gout patients at high risk for SCARs, including Korean patients with chronic renal insufficiency, should be determined. However, whether such genotyping is cost‐effective is unknown. This study evaluated the cost‐effectiveness of HLA–B5801 genotyping for the treatment of gout in patients with chronic renal insufficiency in Korea.